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A B S T R A C T   
Background: The Sda antigen and corresponding biosynthetic enzyme B4GALNT2 are primarily expressed in 
normal colonic mucosa and are down-regulated to a variable degree in colon cancer tissues. Although their 
expression profile is well studied, little is known about the underlying regulatory mechanisms. Methods: To 
clarify the molecular basis of Sda expression in the human gastrointestinal tract, we investigated the transcrip-
tional regulation of the human B4GALNT2 gene. The proximal promoter region was delineated using luciferase 
assays and essential trans-acting factors were identified through transient overexpression and silencing of several 
transcription factors. Results: A short cis-regulatory region restricted to the − 72 to +12 area upstream of the 
B4GALNT2 short-type transcript variant contained the essential promoter activity that drives the expression of 
the human B4GALNT2 regardless of the cell type. We further showed that B4GALNT2 transcriptional activation 
mostly requires ETS1 and to a lesser extent SP1. Conclusions: Results presented herein are expected to provide 
clues to better understand B4GALNT2 regulatory mechanisms.   
1. Introduction 
The histo blood group antigen Sda was discovered long ago [1,2]. It is 
the only antigen of the Sid system [3]: mostly expressed on red blood 
cells, it is also detected in colon and kidney tissues as well as in urine and 
saliva, as reviewed recently [4]. In the human healthy colon, this sia-
lylated trisaccharide (GalNAcβ1-4(NeuAcα2-3)Galβ1-) is primarily 
found on core 3 O-glycans of mucins [5] and, in colorectal cancer cell 
lines, it is described on core 1 and core 2 O-glycans of mucins [6]. It has 
long been observed that this Sda epitope is drastically down-regulated in 
colon cancer to the benefit of the sialyl Lewis x (sLex, NeuAcα2-3Galβ1-4 
[Fucα1-3]GlcNAc-) epitope; however, the control mechanisms regu-
lating this balanced expression remain unknown. 
The human B4GALNT2 gene encodes the Sda synthase (i.e. the β-1,4- 
N-acetylgalactosaminyltransferase 2), which was cloned concomitantly 
by two independent groups from the colonic Caco-2 cells [7,8]. The Sda 
synthase catalyzes the transfer of an N-acetylgalactosamine residue to 
an α2,3-sialylated galactose on either an O- or N-glycan in vitro [8] and 
in colon biopsies [9] or to an extended carbohydrate chain of glycolipid 
like sialylparagloboside in stomach [10]. The human B4GALNT2 gene is 
located on chromosome 17q21.33 and contains 11 coding exons. 
Interestingly, previous studies using Northern blot [8] and PCR analyses 
([7] suggested the existence of multiple transcripts diverging in their 5′- 
and 3′-untranslated region (UTR). Five B4GALNT2 transcripts were 
expressed in the human colon and to a lower extent in ileum, stomach 
and kidney and 5′-rapid amplification of cDNA ends (5’-RACE) analysis 
conducted in differentiated Caco-2 cells demonstrated the existence of at 
least two transcriptional start sites (TSS) and two alternative first exons 
(AFE) in these cells. The long exon 1 noted exon 1 L encompasses 253 
nucleotide (nt) (59 nt untranslated region (UTR) +194 nt coding region 
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(CR), and the short exon 1 known as exon 1S is 38 nt long (24 nt UTR +
14 nt CR), leading to two transcript variants referred to as SF- and LF- 
type that differ at their 5′-end [8]. Since both exon 1 L and 1S contain 
a translational start site, B4GALNT2 drives the expression of two distinct 
B4GALNT2 protein isoforms, a 506 amino-acids (aa) short form and a 
566 aa long form exhibiting a very long cytoplasmic N-terminus. 
Interestingly, expression of these two protein isoforms in the colon 
cancer LS174T cells has shown that i) the shorter isoform has higher 
biosynthetic activity than the long form [11], ii) the longer isoform 
exhibits an additional post-Golgi subcellular localization [12] and iii) 
both the long and short B4GALNT2 isoforms are able to induce the 
expression of Sda and the inhibition of sLex antigens on glycoproteins 
from LS174T cells [11]. A third AFE and a 51 nt middle exon 1 (exon 
1M) were originally predicted in GenBank (Accession number 
NM_001159388) [4] uncovering the existence of a third B4GALNT2 
transcript variant. This latter could be amplified using PCR, cloned and 
sequenced from CCD 841 CoN cells, stomach and colon samples [9]. No 
translational start codon (ATG) can be detected in exon 1 M, and the first 
in frame ATG is located in exon 2, downstream the transmembrane 
domain. Therefore, this transcript variant would drive the expression of 
a third B4GALNT2 isoform of 479 aa lacking its transmembrane domain, 
supporting the observations made by Western blot of the existence of 
shorter isoforms [9]. Nonetheless, PCR analyses of these transcript 
variants in colonic cells and human biopsies demonstrated that the short 
transcript variant was primarily expressed and dramatically down- 
regulated in cancer colon, whereas the long and middle variants were 
barely detectable [9]. The normal colon cells CCD 841 CoN expressed 
high levels of the short transcript variants and low levels of the long 
transcript variant whereas the cancer cell lines HT-116 did not express 
the B4GALNT2 gene. These previous data strongly suggested an 
important point of B4GALNT2 gene regulation at the transcriptional 
level. As for many other carbohydrate epitopes [13], Sda biosynthesis 
appears to be regulated at multiple levels in the gastrointestinal tract 
and regulation of B4GALNT2 is particularly complex. In the past, it has 
been shown that promoter hypermethylation of B4GALNT2 silenced the 
expression of this gene in colon and gastric cancer cell lines and tissues, 
which might be related to aberrant expression of cancer-associated sLex 
antigen [14,15]. However, a recent study unveiled the important but 
unusual role of CpG sites methylation in the B4GALNT2 gene since 
methylation of an intron-located open-sea site between exon 6 and 7 
rather increased B4GALNT2 expression [16] highlighting the complex 
regulatory mechanisms underpinning B4GALNT2 expression in the 
digestive tract. 
As a starting point, we aimed in this study to clarify the molecular 
basis of Sda expression in the human gastrointestinal tract. For that 
purpose, we explored transcriptional regulation of the human 
B4GALNT2 gene in various gastro-intestinal cultured cells. We used 5′- 
RACE and a dual luciferase assay for sequential deletion and site- 
directed mutagenesis to identify transcriptional start site (TSS) and 
delineate the core promoter region. We determined the cis-acting ele-
ments and transcription factors (TF) that regulate B4GALNT2 expression 
in CCD 841 CoN colon cells using transient overexpression and silencing 
of SP1, ETS1 and DMTF1, and chromatin immunoprecipitation (ChIP) 
assay. Our results indicating that 5′-flanking region at positions − 72 to 
+12nt relative to the B4GALNT2 short variant start codon is critical for 
B4GALNT2 transcription and mRNA expression in colon pave the way to 
unravel molecular mechanism underpinning B4GALNT2 expression. 
2. Material and methods 
2.1. Plasmids construction and site-directed mutagenesis 
Genomic DNA from HT-29 cells was prepared with Genomic DNA 
Mini Kit (Thermo Fisher Scientific Bioscience, Villebon sur-Yvette, 
France).) following manufacturer’s instructions. The genomic 
sequence located between − 1559 bp and + 675 bp was amplified by 
PCR using the primer pairs P1KpnI and P1HindIII (Supplemental Table 
1). The PCR product was cloned into the pCR®2.1 TOPO vector (Thermo 
Fisher Scientific Bioscience, Villebon sur-Yvette, France). The promoter 
sequence was then isolated by digestion of the vector using KpnI and 
HindIII restriction sites. The purified fragment was sub-cloned into 
pGL3Basic vector (Promega, Madison, USA) upstream of the Firefly 
luciferase gene at KpnI/HindIII sites. The resulting plasmid was designed 
pGL3(− 1559/+675). Truncated promoter constructs were generated 
either by enzymatic digestions, ends blunting and ligation (Supple-
mental Table 2) or PCR (Supplemental Table 1) or substitution (Sup-
plemental Table 3). All plasmid constructs were sequenced (GATC 
Biotech, Köln, Germany). 
The SP1.1, SP1.2, SP1.3, DMTF1/ETS1, DMTF1 and ETS1 consensus 
sequences in the B4GALNT2 promoter region present in the pGL3(− 83/ 
+72) plasmid were mutated by base substitution using a Quick-Change 
mutagenesis kit (Stratagene, La Jolla, CA) according to the manufac-
turer’s protocol, using the mutagenetic oligonucleotide primers shown 
in Supplemental Table 1. The PCR conditions were a first denaturation 
step at 95 ◦C, followed by 12 cycles: 95 ◦C for 30 s, 55 ◦C for 1 min, 68 ◦C 
for 5 min. The PCR product was then digested with the DpnI restriction 
enzyme for 1 h at 37 ◦C. After bacterial transformation using XL1-Blue 
competent cells and plasmid purification, all plasmids were sequenced 
to check the mutation of each site. 
2.2. Cell culture, transient transfections (Luciferase assays, 
overexpression and siRNA) and luciferase assays 
The human colon carcinoma cell line HCT-116 (ATCC, CCL-247) and 
the human cervical cancer cells HeLa (ATCC CCL-2) were routinely 
grown in Dulbecco’s Modified Eagle Medium (DMEM) containing 2 mM 
glutamine and 10% fetal calf serum, at 37 ◦C in an atmosphere of 5% 
CO2. The human normal colon epithelial cell line CCD 841 CoN (ATCC, 
CRL-1807) and the human normal colon fibroblast cells CCD 112 CoN 
(ATCC CRL-1541) were grown in Eagle’s Minimal Essential Medium 
(EMEM) with 2 mM glutamine supplemented with 10% fetal calf serum. 
The human gastric carcinoma cells MKN-45 (DSMZ, ACC-409) was 
grown in Roswell Park Memorial Institute (RPMI) medium supple-
mented with 2 mM glutamine supplemented with 20% fetal calf serum. 
The cell lines were obtained by the ATCC (LGC Standards SARL, Mol-
sheim, France). 
2.3. Transient transfections 
To assay Luciferase activity, HeLa, HCT-116, CCD 841 CoN and 
MKN-45 cells (70% confluency) were transfected using lipofectamine 
(Thermo Fisher Scientific Bioscience, Villebon sur-Yvette, France).) ac-
cording to the manufacturer’s instructions, with 1.5 μg of pGL3 con-
structions and 20 ng of control Renilla plasmid in Ultra MEM medium. 
After 6 h, the medium was replaced by fresh culture medium and further 
incubated for 48 h. Cells were then washed with Phosphate Buffered 
Saline (PBS), lysed with 80 μl of Passive Lysis Buffer (PLB, Dual Lucif-
erase Reporter Assay System, Promega, Madison, USA) and 20 μl of 
lysate were used to measure the luciferase activity. Luminescence was 
measured with the Centro luminometer (Berthold Technologies, Bad 
Wildbad, Germany). 
For transient transfection with small interfering RNA (siRNA), 
oligonucleotide duplexes (ON-TARGETplus SMARTpool; Horizon Dis-
covery; Cambridge; UK) targeting ETS1, DMTF1, SP1 and a nontargeted 
oligonucleotide duplex (ON-TARGET plus siCONTROL; Horizon Dis-
covery; Cambridge; UK) as a negative control, were used in the trans-
fection experiments with Lipofectamine 2000 Transfection Reagent 
(Thermo Fisher Scientific; Waltham; MA; USA). Briefly, CCD 841 CoN 
cells were grown to 80% confluence. ETS1, DMTF1 and SP1 siRNAs 
(200 pmol) and control siRNA (200 pmol) were incubated with the 
transfection reagent at room temperature for 25 min, to form complexes, 
which then were added to 6-well plates containing cells and medium. 
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After 4 h in a 5% CO2 atmosphere at 37 ◦C, the delivery mix was replaced 
with EMEM supplemented with 10% fetal bovine serum (FBS). The 
following day, the cultures were split and the delivery mix containing 
100 pmol siRNAs was re-applied. The cells were harvested 24 h later and 
used for further analysis. 
To overexpress ETS1 and DMTF1, the full-length sequence of ETS1 
and DMTF1 cDNA was cloned into the pcDNA3.1 vector (pcDNA3.1- 
ETS1 kindly provided by Dr. M. Aumercier UMR CNRS 8576, Villeneuve 
d’Ascq and pcDNA3.1-DMTF1α kindly provided by Dr. B. Torbett, 
Scripps Research Institute, La Jolla, CA). An empty pcDNA3.1 vector 
was used as a negative control. To overexpress SP1, the full-length 
sequence of SP1 cDNA was cloned into the pCMV4 vector (pCMV4- 
Sp1 [17]. 
CCD 841 CoN cells were cultured to 80% confluence and then 
transfected with the various vectors (2 μg) using Lipofectamine 2000 
Transfection Reagent (Thermo Fisher Scientific; Waltham; MA; USA) 
according to the manufacturer’s instructions. After 24 h, the cells were 
harvested and used for further analysis. 
2.4. Preparation of cell lysate and electrophoretic mobility shift assay 
(EMSA) 
EMSAs were performed with the Light Shift Chemiluminescent EMSA 
Kit (Thermo Scientific, Illkirch, France) following the manufacturer’s 
recommendations, but the binding reaction volume was scaled down to 
10 μl. In the case of G/C-rich sequences, the binding reactions contained 
50 mM KCl, 5% glycerol, 5 ng/μl of poly(dI⋅dC), and no detergent NP-40 
or MgCl2. Nuclear extracts were prepared using the NE-PER extraction 
kit (Thermo Fisher Scientific Bioscience, Villebon sur-Yvette, France), 
and 1 μl of extract (3–4 μg of protein) was added to each binding re-
action. DNA probes were biotinylated at the 5′-end (Eurogentec, 
Belgium) (Supplemental Table 4). For the control supershift assay, the 
anti-SP1 (PEP2; sc-59) polyclonal antibody was added in the binding 
reaction before addition of labeled DNA probes. DNA/protein complexes 
were separated by 6% native PAGE, transferred to nylon membrane, 
cross-linked under UV light, and detected according to the kit protocol. 
2.5. Chromatin immunoprecipitation ChIP assay 
Chromatin immunoprecipitation assays (ChIP) were achieved basi-
cally as previously described [18]. Briefly, CCD 841 CoN and HCT-116 
cells (1 × 106 cells per antibody) were treated with 1% (v/v) formal-
dehyde for 10 min at room temperature and cross-links were quenched 
with glycine at a final concentration of 0.125 M for 5 min. Cells were 
rapidly rinsed with ice-cold Dulbecco-PBS (D-PBS) containing a cocktail 
of protease inhibitors (Roche Diagnostics, Penzberg, Germany) and 
scraped off and collected by centrifugation at 700 ×g for 5 min at 4 ◦C, 
before being resuspended in lysis buffer (10 mM Hepes-KOH, pH 7.9, 10 
mM KCl, 1.5 mM MgCl2 and 0.1% Nonidet P40) containing protease 
inhibitors and incubated for 10 min on ice. Chromatin was sheared with 
the Bioruptor system (Bioruptor® Plus, Diagenode, Seraing, Belgium). 
The extracts were sonicated for 10 pulses of 30 s each with a 30 s rest 
between each pulse at 200 W at 4 ◦C. After clearing by centrifugation at 
10,000 ×g for 10 min at 4 ◦C, the supernatant was fractionated and 
precipitated with either 3 μg of the specific antibody anti-ETS1 (C-20, sc- 
350), anti-DMTF1 (S-19, sc-6552) or the anti-SP1 at 4 μg (PEP2, sc-59) 
or normal goat IgGs (Sc-2028) from Santa Cruz biotechnology (Santa 
Cruz biotechnology, Dallas, Texas, USA) and normal Rabbit IgG at 4 μg 
(12–370, Millipore, Burlington, Massachusetts, United-States). An 
aliquot of the total supernatant was removed as input control. Immu-
noprecipitation was performed overnight on a rotating platform at 4 ◦C, 
a Protein A/G magnetic bead mix (Invitrogen) was then added and left 
for another 3 h as previously described [19]. Magnetic beads were 
collected and washed 5 times sequentially in Low Salt Immune Complex 
wash buffer (20 mM Tris/HCl (pH 8.0), 150 mM NaCl, 2 mM EDTA, 
0.1% SDS and 1% Triton X-100), High Salt buffer (20 mM Tris/HCl (pH 
8.0), 500 mM NaCl, 2 mM EDTA, 0.1% SDS and 1% Triton X-100) and TE 
buffer (10 mM Tris/HCl (pH 8.0) and 1 mM EDTA). The complexes were 
eluted with 210 μl of elution buffer [0.05 M Tris/HCl (pH 8.0), 10 mM 
EDTA and 1% SDS] after a 15 min incubation at 65 ◦C. Formaldehyde 
cross-links were reversed with 0.2 M NaCl at 65 ◦C overnight. Chro-
matin-associated proteins were digested with Proteinase K at 37 ◦C for 1 
h and the DNA was purified with the Wizard® DNA Clean-up (Promega, 
Madison, USA). Samples were then subjected to qPCR analysis as 
described previously using ChIP primers pairs (Supplemental Table 5). 
ChiP-qPCR data were normalized using the percent input method where 
Ct values obtained from the ChIP samples are divided by signals ob-
tained from the adjusted input signal. The percentage of input was 
therefore calculated using this formula: 100*2^(adjusted input - Ct(IP). 
The percent input from relevant antibodies was then compared to con-
trol IgG. 
2.6. RNA extraction, cDNA synthesis, determination of transcription start 
site in cells and biopsies (5’-RACE) and Q-PCR 
The Rapid Amplification of cDNA 5′ ends (5′-RACE) was performed 
with the First Choice® RLM-RACE kit (Ambion) according to the pro-
tocol provided by the manufacturer. Briefly, 10 μg of total ARN were 
treated with Calf Intestine Alkaline Phosphatase (CIP) and then with 
Tobacco Acid Pyrophosphatase (TAP). A 45 base RNA Adapter oligo-
nucleotide (Supplemental Table 1) was ligated to the RNA using T4 RNA 
ligase. A reverse transcription was performed with random decamers. 
After synthesis of the first strand cDNA, nested PCR was performed using 
AccuTaq TMLA DNA polymerase (Sigma-Aldrich, Saint Quentin Fal-
lavier, France). 5’-RACE Outer Primer/5’RACE B4GALNT2 Outer Primer 
and 5’RACE Inner Primer/5’RACE B4GALNT2 Inner Primer pairs were 
used for a first and second PCR round, respectively. PCR products were 
size-separated by agarose gel electrophoresis, subcloned into pCR2.1- 
TOPO vector (Invitrogen) and sequenced by GATC Biotech (Köln, 
Germany). 
Gene expression was analyzed by quantitative PCR (qPCR) using the 
Mx3005p Quantitative System (Stratagene, La Jolla, CA, USA). PCR 
reaction (25 μL) contained 12.5 μL of the 2× Brilliant SYBR Green qPCR 
Mastermix (Thermo Fischer Scientific, Rockford, USA), 300 nM of 
primers and 4 μL of cDNA (dilution 1:40). Thermal cycling profiles 
analysis of amplification performed using Mx3005p software. All ex-
periments were performed in triplicate using three different biological 
samples. The quantification was achieved by the method described by 
Pfaffl [20]. 
2.7. Bioinformatic analyses: genomatix and genetic regulatory network of 
transcription and pathway crosstalk 
In silico analysis of the promoter was performed with BLAST analysis 
of the human genome of the NCBI database. The core promoter sequence 
was analyzed with MatInspector 8.0 (www.genomatix.de) using 
TRANSFAC 8.4 matrices with “core similarity 0.95” and “matrice simi-
larity: optimized”. 
For the gene regulatory network, a list of 45 genes including the 
three transcription factors ETS1, SP1 and DMTF1 and 42 glyco-genes 
involved in N-glycan, O-glycan and glycolipid biosynthesis pathways 
(list available in supplementary data) was first created. The master 
regulators of these 45 genes were thus searched with the iRegulon v1.3 
app [21] for the Cytoscape network visualization and analysis software 
v3.8.2 [22,23] in the 500 bp upstream the transcription start site (results 
and parameters available in supplemental data). For the creation of the 
regulatory network, a minimum NES score = 2 was considered for the 
identification of targets of the three input transcription factors and a 
NES score = 3 was used for the identification of master regulators that 
target B4GALNT2. The lowest threshold was used in order to maximize 
the possible knowledge of targets of the input transcription factors 
whereas the highest was used in order to limit the number of other 
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regulators and keep the network readable. The regulations described in 
this article were added to the network. The glyco-genes that were 
identified as co-differentially expressed with B4GALNT2 in the work of 
Pucci et al. [4] were annotated in the network as elliptic nodes. Self- 
loops were removed. 
COlorectal ADenocarcinoma (COAD) data of The Cancer Genome 
Atlas (TCGA) database were used through the UALCAN webtool [24]. 
Individual expression levels of B4GALNT2, SP1, DMTF1 and ETS1 for 
normal (n = 41) and primary tumor (n = 286) samples were extracted 
and represented as box-whisker plots in Fig. S3A. Heatmaps of each gene 
of the regulatory network except MUC5B (data not available in UAL-
CAN) were extracted as well and depicted in Fig. S3B. The same data 
were used and log2 fold change of medians of primary tumor vs normal 
conditions were computed for each gene of the regulatory network and 
integrated as a gradient from blue (log2FC ≤ − 3) to white (log2FC = 0) 
and red (log2FC ≥ 3) in Fig. 8; only signals with statistical significance 
≤0.05 were colored, others are white. For correlation analysis data, gene 
expression of B4GALNT2, ETS1, SP1 and DMTF1 were extracted from 
The Cancer Genome Atlas (TCGA COADREAD, https://cancergenome. 
nih.gov/) for 524 colorectal cancer patients using the cBioPortal web-
site. Transcript expression values (z-scores) relative to normal samples 
were retrieved as RSEM (Batch normalized from Illumina HiSeq_RNA-
SeqV2). For expression analysis in normal samples, B4GALNT2, ETS1, 
SP1 and DMTF1 gene expression profiles were downloaded from the 
NCBI Gene Expression Omnibus (GEO) database with accession number 
GSE44076 (https://www.ncbi.nlm.nih.gov/geo/). GSE44076 is a data-
set containing gene expression profiles from the Colonomics project that 
includes expression data of paired normal adjacent mucosa and colo-
rectal tumor samples from 98 individuals and 50 healthy colon mucosae 
from healthy donors. Prior to analysis, probe identification in the 
GPL13667 platform (Affymetrix Human Genome U219 Arrays) were 
converted into standard gene symbols. For genes with more than one 
probe set in the array, average values were used. TCGA and Colonomics 
data analyses were processed using R studio (https://rstudio.com/). 
Pearson’s R correlation coefficient was used to assess relationships be-
tween transcript expression levels of B4GALNT2 and ETS1, SP1 and 
DMTF1 into the two data series. The r values and p values were calcu-
lated for each combination of genes in all the samples of the TCGA 
COADREAD dataset and in healthy colon mucosa samples in the Colo-
nomics dataset. p < 0.05 was considered as statistically significant. Heat 
maps were generated to visualize gene expression data of the four genes 
of interest across all Colonomics samples. Expression levels were stan-
dardized (centered and scaled) within rows for visualization. 
2.8. Statistical analyses 
Statistical analyses were performed with Graphpad Prism software 
version 4.0 (Graphpad softwares Inc., La Jolla, CA, USA) using the 
ANOVA test. Results were deemed significant for p values less than 0.05 
(p < 0.05). * p < 0.05; ** p < 0.01 *** p < 0.001. 
3. Results 
3.1. Identification of the B4GALNT2 gene transcriptional start sites (TSS) 
We have previously reported the existence of at least two TSS and 
two AFE giving rise to two transcript variants (Short Form (SF) and Long 
Form (LF)) in the colon cancer cell line Caco-2 [8] and that the CCD 841 
CoN and in CCD 112 CoN cell lines as well as healthy colon biopsy 
expressed the highest level of B4GALNT2 transcripts [9]. To locate the 
transcriptional start sites in healthy colon, the 5′-UTR of B4GALNT2 
transcripts were analyzed using 5′-RACE in the 2 cell lines and in healthy 
colon as described in the Material and Methods section. Different 5′- 
RACE products were observed on agarose gel (Fig. 1A) and their 
sequencing demonstrated the existence of multiple TSS and AFE in 
healthy colon. The majority of the amplified sequences from CCD 841 
CoN cells and healthy colon biopsy were of the SF-type indicating that 
B4GALNT2 transcription primarily started within exon 1S. Two different 
TSS were positioned at − 95 and -24 nt relative to the first in frame start 
codon ATG in exon 1S designated as (+1) (Fig. 1B, transcripts 1, 2). 
Another transcript of the LF-type with a unique TSS located − 154 nt 
upstream the start codon in Exon 1 L was also detected in the cell lines 
(Fig. 1B, transcript 3) and more specifically in the CCD 112 CoN cells. 
Interestingly, a few sequences corresponding to a transcript of the 
middle form (MF)-type with a TSS located − 81 nt upstream the start 
codon in Exon 2 (Fig. 1B, transcript 4) were detected in the healthy 
colon biopsy. These data established the existence of three different sets 
Fig. 1. Mapping the transcriptional start sites (TSS) of the human B4GALNT2 
gene in colon cells using 5’-RACE. A) Agarose gel electrophoresis of 5’-RACE 
amplification products shows products at approximately 600 bp primarily in 
CCD 112 CoN cells and barely detected in CCD 841 CoN cells. This corresponds 
to a transcript of the LF-type with a unique TSS located − 154 nt upstream the 
start codon in Exon 1 L corresponding to transcript 3 depicted below. Less 
intense bands seen below were also extracted and sequenced and found to 
correspond to incomplete synthesis by the reverse transcriptase. Amplification 
products visualized at approximately 340 bp in CCD 841 CoN cells and colon 
sample were mostly of the SF-type transcript variant and correspond to tran-
scripts 1 and 2 shown below. These two transcripts correspond to two different 
TSS positioned at − 95 and -24 nt relative to the first in frame start codon ATG 
in exon 1S, designated as (+1). Interestingly, these amplification products 
detected in the healthy colon biopsy also include a few sequences corre-
sponding to a transcript of the MF-type with a TSS located − 81 nt upstream the 
start codon in Exon 2, corresponding to transcript 5 described below. A negative 
control of the 5′-RACE with no ARN is shown on the right side of the gel. B) 
Schematic representation of the 5′-flancking region of B4GALNT2 gene and four 
transcripts variants (1–4) found in colonic cells. This scheme indicates the 
differences in the 5′UTR of B4GALNT2 transcripts in colon. The bent arrows 
indicate the various transcription start positions. The arrows indicate the three 
ATG in each alternative first exon (AFE) 1S and 1L and in exon 2 and their 
position relative to the first methionine codon is indicated above. 
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of TSS located on three different AFE of the B4GALNT2 gene in healthy 
colon and normal colon cell lines corroborating previous observations 
and confirming the predominant expression of SF-type transcripts [9]. 
3.2. Delineation of the B4GALNT2 promoter region 
We next sought to determine the promoter region of the B4GALNT2 
gene. For that purpose, the genomic sequence located between − 1559 
bp and + 675 bp encompassing the three AFE was cloned into the 
promoter-less pGL3Basic upstream the firefly luciferase gene to generate 
the pGL3(− 1559/+675) reporter plasmid (Fig. 2A). The normal colon 
CCD 841 CoN cells were chosen for initial transient transfections since 
they express both the SF- and LF-type transcript variants of B4GALNT2 
and the colon cancer HCT-116 because they do not express B4GALNT2 
[9]. In addition, the gastric carcinoma MKN-45 cells and cervix cancer 
HeLa cells which express very low levels or no B4GALNT2 [9] were also 
used as control recipient cells (Fig. 2). However, not much luciferase 
activity could be detected for the pGL3(− 1559/+675) plasmid (Fig. 2B). 
Therefore, several 5′- or 3′-deleted constructs were made that were 
transfected into the different cell types for subsequent luciferase assays. 
The results presented in Fig. 2B show that all constructs lacking the 
+72/+675 genomic region exhibit increased activities compared to the 
pGL3Basic plasmid used as a reference. Maximal promoter activities 
were obtained for pGL3(− 83/+72) construct, which proved to be the 
most active whatever the cell line used for transfection (17.7-, 15-, 14.8- 
and 7.1-fold increased activity into CCD 841 CoN, HCT 116, HeLa and 
MKN-45, respectively) (Fig. 2B). These first experiments enabled us to 
delineate a B4GALNT2 promoter region (− 83/+72) containing the 
positive regulatory elements responsible for constitutive activity 
regardless of the cell type. 
3.3. Characterization of the proximal promoter region of B4GALNT2 
The genomic region − 277/+236 of the human B4GALNT2 gene 
encompassing exon 1S and part of exon 1 L and the putative promoter 
region − 83/+72 delineated above was analyzed with the MatInspector 
8.0 program (Genomatix) with core similarity of 0.95 and an optimized 
matrix similarity. This bioinformatic analysis did not identify TATA- nor 
CAAT-box in the delineated B4GALNT2 promoter, but several GC-boxes 
were observed. These features and the heterogeneous TSS identified for 
B4GALNT2 transcripts in colon, are structural features typical of the so- 
called housekeeping genes and most glycosyltransferase genes described 
up to now. However, it led to the identification of several putative 
transcriptional factor binding sites (Supplemental Table 6 in supple-
mental data) including those for factors belonging to the specificity 
protein (SP) transcription factor family like SP1 (Stimulating protein 1) 
and for transcription factors involved in various cellular processes like 
cell proliferation, cell cycle or growth such as DMTF1 (Cyclin D binding 
myb-like protein 1) and ETS1 (E26-transformation specific), illustrated 
in Fig. 3A. Three SP1 binding sites (consensus sequence G/TGGGCGGG/ 
AG/AG/T) were found at positions -72/-63 and -18/-9 upstream the SF- 
variant start codon and at +8/+17, upstream the LF-variant start codon 
and one DMTF1 and/or ETS binding site (consensus sequence CCCG(G/ 
T)ATGT) [25] was found at -33/-25 (Fig. 3A). 
We then assessed the possibility of two promoters driving the 
expression of the two major types of B4GALNT2 transcripts (SF- and LF- 
variants). For that purpose, we examined in more details the promoter 
activity of the genomic regions upstream the two major AFE and 
generated additional constructs spanning ~250 bp of each genomic 
region. The pGL3(+1/+234), pGL3(+14/+234) and pGL3(+1/+72) 
constructs including genomic sequences upstream the LF-translational 
start site were transfected into CCD 841 CoN or HCT-116 cells and 
Fig. 2. Promoter activity of serial deletion constructs of the human B4GALNT2 gene. A) Schematic representation of the cloned B4GALNT2 genomic region (− 1559/ 
+675 nt region) cloned in the luciferase (LUC) reporter plasmid. Nucleotides are numbered relative to the first base of the methionine codon of the short transcript 
variant and B) luciferase activities of the B4GALNT2 deletion mutants relative to the mock (pGL3Basic) in four cell lines CCD 841 CoN, HCT-116, MNK-45 and HeLa 
cells. The experiments were carried out in triplicates and data are the mean +/− S.D. 
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showed almost no luciferase activity compared to the pGL3 basic 
plasmid (Fig. 3B). The 3′-deleted construct pGL3(+14/+72) showed 
increased luciferase activity. Interestingly the pGL3(+27/+72) 
construct showed the highest luciferase activity, whereas the pGL3(+1/ 
+27) had no activity. These results further suggested the presence of cis- 
acting motifs enhancing promoter activity in the +27/+72 region and 
the presence of a negative regulatory element within the +1/+27 re-
gion. After deletion of the − 277/− 84 region, the luciferase activity of 
pGL3(− 84/+1) construct is comparable to the luciferase activity of 
pGL3(− 277/+1), suggesting that a core promoter region for the 
B4GALNT2 gene is located within the sequence − 84/+1 upstream of the 
exon 1S. The pGL3(− 277/+1) construct including genomic sequences 
upstream the SF-translational start site transfected into CCD 841 CoN or 
HCT-116 cells showed the highest activity (Fig. 3C). The pGL3(− 84/+1) 
showed similar level of activity compared to the pGL3(− 277/+1) 
whereas the 3′-deleted construct pGL3(− 277/− 84) showed less or no 
activity compared to pGL3basic. These data further suggested that the 
cis-acting elements enhancing promoter activity of the SF-variant are 
located in the − 84/+1 region. These conclusions are supported by 
synergistic activity of the pGL3(− 84/− 24) and pGL3(− 24/+1) con-
structs. Since the major form expressed in healthy colon is the SF-type 
transcript variant [9], we next focused on the regulation of this variant. 
Gel electrophoresis mobility shift assay (EMSA) was used to detect 
protein complexes with nucleic acids in the various regions of interest 
(Fig. 3D). EMSA experiments carried out using CCD 841 CoN and HCT- 
116 nuclear extracts and the 5′-biotinyated − 35/+25 probe, which 
encompasses the DMTF1, ETS1, Sp1.2 and Sp1.3 binding sites revealed 
two major complexes (left panel, Fig. 3D). These complexes were 
competed with 200-fold excess of unlabeled and specific consensus 
sequence oligonucleotides for competition and were more detectable 
with the protein extracted from the HCT-116 cells. Supershift assays 
using antibody against SP1 and CCD 841 CoN nuclear extracts confirmed 
implication of this TF (Supplemental Fig. S1). The potential implication 
of the DMTF1, ETS1 and Sp1.2 binding sites positioned upstream the 
Fig. 3. Nucleotide sequence of the 5′-flanking region of the B4GALNT2 gene and promoter activities A) Genomatix analysis of the − 277/+234 nt genomic region. 
Consensus TF binding motifs for SP1, ETS1, DMTF1 were identified in the 5′-flanking region of the B4GALNT2 gene. Nucleotides are numbered relative to the first 
base of the methionine codon of the short transcript variant. The 5′-untranslated region (5’-UTR) of each transcript variant is indicated with bold characters and the 
translated regions are indicated in red. Arrowheads indicate the location of transcriptional sites. B) Promoter activity of the long B4GALNT2 transcript promoter (+1/ 
+234). A schematic illustrating this B4GALNT2 gene region including the two alternative first exons (AFE) 1S and 1 L is given above the representation of promoter 
deletion constructs corresponding to the long B4GALNT2 transcript variant cloned in the luciferase (LUC) reporter vector. Their corresponding luciferase activities 
(relative to the mock pGL3Basic) in CCD 841 CoN and HCT-116 cells are represented on the right. C) Promoter activity of the short B4GALNT2 transcript promoter 
region (− 277/+1). A schematic illustrating this B4GALNT2 gene region upstream of the first exon 1S is given above the representation of the promoter deletion 
constructs corresponding to the short B4GALNT2 transcript variant cloned in the luciferase (LUC) reporter vector. Their corresponding luciferase activities (relative to 
the mock pGL3Basic) in CCD 841 CoN and HCT-116 cells are represented on the right. D) Electrophoresis mobility shift assay (EMSA) of the B4GALNT2 promoter 
region. The three 5′-biotinyated-labeled probes (− 35/+25, − 40/− 6 and + 13/+72) containing SP1-binding sites 2 and 3, the ETS1-binding site and the DMTF1- 
binding site are positioned below the B4GALNT2 gene in the region corresponding to the promoter of the short transcript. The labeled probes were incubated 
with either CCD 841 CoN or HCT-116 nuclear extracts. For each panel, lane 1 correspond to the negative control with no nuclear extract. The free labeled probe (F) is 
indicated by an arrow on the left side and the specific DNA-protein complexes are pointed by arrowheads on the right side of the gel. (*) indicate non-specific 
complexes. (− ) indicate no competitor and (+) indicate the presence of an excess of the unlabeled probe competing with the formation of the specific DNA- 
protein complexes. 
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AFE 1S was confirmed using the 5′-biotinyated − 40/− 6 probe, with the 
formation of four protein-DNA complexes (middle panel, Fig. 3D). One 
complex was equally detectable with the protein extracted from the 
CCD-841 CoN and HCT 116 cells, one was more detectable with the 
protein extracted from the HCT-116 cells and two complexes were 
detectable only with the protein extracted from the HCT-116 cells. 
Finally, the 5′-biotinyated +13/+72 probe containing no major binding 
sites upstream the AFE 1 L revealed only minor complexes with proteins 
extracted from HCT-116 cells (right panel, Fig. 3D). The other com-
plexes were not outcompeted by the unlabeled probe and therefore are 
considered as non-specific complexes. Taken together, these data indi-
cate the presence of several specific complexes, that are more readily 
detectable with proteins extracted from the HCT-116 cells, within the 
− 84/+1 core promoter region. In addition, one complex more detect-
able with proteins extracted from CCD 841 CoN cells was identified 
within the +27/+72 region. 
3.4. Contribution of ETS1, SP1 and DMTF1 elements to human 
B4GALNT2 promoter activity 
To get insights into the role of each identified TF binding site and 
further define the specific elements that contribute to the proximal 
promoter activity, we performed site-directed mutagenesis. We gener-
ated a series of B4GALNT2 promoter constructs with mutations in the 
ETS1, DMTF1 and SP1 elements of the pGL3 (− 83/+72) construct, 
which served as a reference. DMTF1 and ETS1 share the same binding 
site GCCGGATGT in the B4GALNT2 gene (Fig. 2). However, Hirai and 
Sherr reported that CCCGTATGT could specifically bind DMTF1 
whereas CCCGGAAGT binds specifically ETS1 [25]. Therefore, the 
ACTTCCGGC (ETS1* only) and the ACATACGGC (DMTF1* only) mu-
tations were brought in the pGL3(− 83/+72) plasmid to abrogate 
DMTF1 and ETS1 binding, respectively and the ACATCTAGC mutation 
to abrogate binding of both TFs. The various mutated pGL3(− 83/+72) 
constructs were transfected in CCD 841 CoN and HCT-116, as previously 
described. Interestingly, mutation of the ETS1 binding site where only 
DMTF1 can bind did not seem to have an impact on the promoter ac-
tivity, but the combined mutation of the ETS1 and DMTF1 sites led to 
relevant 61 to 66% promoter inhibition in CCD 841 CoN and HCT-116, 
respectively, (Fig. 4). Finally, mutation of the DMTF1 binding site, 
where only ETS1 can bind increased significantly B4GALNT2 promoter 
activity (73–128% in CCD 841 CoN and HCT-116, respectively) (Fig. 4). 
Mutation of the SP1.1 binding site resulted in a significant decrease of 
luciferase activity (~16–40% in HCT-116 and CCD 841 CoN), whereas 
mutations of SP1.2 and SP1.3 binding sites led to a significant increase of 
luciferase activity (~27–34% for SP1.2 in CCD 841 CoN and HCT-116 
and 18–41% SP1.3 in CCD 841 CoN and HCT-116) (Fig. 4). These data 
further suggest the implication of SP1 (at the SP1.1 binding site) and a 
combination of ETS1 and DMTF1 TFs to enhance the B4GALNT2 pro-
moter activity. 
3.5. Identification of transcription factors essential for regulation of 
B4GALNT2 gene 
Firstly, we checked endogenous ETS1, SP1 and DMTF1 TF expression 
in HCT-116 and CCD 841 CoN cell lines by RT-qPCR: all TF were 
expressed in both cell lines, with a higher expression of DMTF1 in both 
cell types (Supplemental Fig. S2A). The overexpression of ETS1, SP1, 
DMTF1 was achieved through transient transfections of expression 
vectors in CCD 841 CoN cells, with a resulting 50 to 100-fold increase of 
TF expression levels (Supplemental Fig. S2B). Our RT-qPCR analysis 
showed that the overexpression of ETS1 and DMTF1 increased the 
expression of the SF B4GALNT2 transcript (50% and 25% increase, 
respectively), whereas SP1 overexpression had no effect (Fig. 5A). The 
same experiments were carried out in HCT-116 cells, which do not ex-
press endogenous B4GALNT2 [9]. However, overexpression of these TFs 
did not induce B4GALNT2 expression (data not shown) further sug-
gesting more complex regulatory mechanisms. Additionally, the inhi-
bition of ETS1, SP1, DMTF1 expression was performed using siRNA 
expression in CCD 841 CoN cells (Supplemental Fig. S2C), which 
resulted in decreased expression of SF B4GALNT2 transcript for the three 
TFs of about 70% for SP1 and 50% for both ETS1 and DMTF1 (Fig. 5B). 
These results suggest that ETS1, SP1 and DMTF1 can modulate 
B4GALNT2 gene expression in normal colon cells. 
Secondly, to confirm direct involvement of these TF, Chromatin 
Immuno-Precipitation (ChIP) experiments were carried out. After 
checking the relative expression of the three TF in CCD 841 CoN using 
qPCR (Supplemental Fig. 2A), chromatin from CCD 841 CoN was 
immunoprecipitated with either anti-ETS1, anti-SP1 or anti-DMTF1 
antibody and isotype IgG as controls. DNA was isolated from each 
immunoprecipitate and the ETS1, SP1 and DMTF1 binding regions in 
B4GALNT2 promoter region were amplified by PCR. Five experiments 
were conducted and representative results are shown in Fig. 6B. Our 
data indicate that ETS1 and SP1 transcription factors bind to B4GALNT2 
promoter in CCD 841 CoN cells. However, no direct binding of DMTF1 to 
the promoter could be detected. 
4. Discussion 
The human B4GALNT2 gene is expressed under various biological 
conditions and most abundantly in healthy colon. However, its expres-
sion is dramatically downregulated in colon cancer [9,26–28] leading to 
disappearance of the Sda determinant and a concomitant increased 
expression of sLex structures on glycoproteins [9,11]. Interestingly, 
recent analysis of transcriptomic data from The Cancer Genome Atlas 
Fig. 4. Mutation analysis of the B4GALNT2 promoter 
activity. The B4GALNT2 transcript promoter region 
(− 83/+72) cloned into the luciferase (LUC) reporter 
vector was used to generate mutated promoter frag-
ments by site-directed mutagenesis of each TF bind-
ing sites SP1 (SP1.1*; SP1.2*; SP1.3*) and both ETS1 
and DMTF1 (DMTF1/ETS1*) binding site; 
DMTF1*only and ETS1* only means that only DMTF1 
and ETS1 can bind to the ETS1 and DMTF1 mutated 
binding site, respectively. Transient transfections of 
these various plasmids were achieved in CCD 841 
CoN and in HCT-116 cells and Luciferase assays were 
performed. Their corresponding luciferase activities 
(relative to the pGL3(− 83/+72)) are represented on 
the right. Data represent the mean +/− S.D. of three 
independent experiments. *: p ≤ 0.05; **: p ≤ 0.01; 
***: p < 0.001; ns: non-significant (vs pGL3(− 83/ 
+72)).   
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(TCGA) database uncovered that high expression of the B4GALNT2 gene 
was associated to good prognosis value in colorectal cancer patients 
[16,29]. In addition, it has long been known that the Sda-glycosylation 
profile of the digestive tract underpins host-microbe interactions and 
modulates susceptibility to infectious microbes as reviewed recently 
[30]. Therefore, deciphering the regulatory molecular mechanism for 
this gene expression is of utmost interest in the field of colon cancer 
biology. 
4.1. Three AFE and three sets of TSS for the B4GALNT2 gene 
Previous studies have shown that the human B4GALNT2 gene coding 
sequence is scattered over 11 exons and that it drives the expression of at 
least 5 distinct transcripts in the digestive tract [8]. Interestingly, the 
mouse b4galnt2 gene, previously known as CT-GalNAc transferase [31] 
differs in its first exon and drives the expression of a unique transcript. In 
this study, we identified the multiple B4GALNT2 TSS using PCR ana-
lyses, as shown to occur for several other glycosyltransferase genes 
including the B4GALNT2 paralog known as B4GALNT1 encoding the 
GM2/GD2 synthase [32], the murine B4GALT1 [33,34] and the human 
sialyltransferase ST3GAL5 encoding the GM3 synthase [35]. Moreover, 
we showed the existence of three sets of TSS located in three distinct AFE 
for the human B4GALNT2 gene, further suggesting the existence of 
multiple promoter regions as described previously for the human 
ST6GAL1 gene [36,37] an unusual feature of the mammalian genes 
gained during the time course of vertebrates’ evolution [38]. In fact, 
most glycosyltransferase genes show a unique first exon with either one 
TSS as for the human ST8SIA1 (e.g. GD3 synthase) [39,40] or the 
B4GALT3 genes [41], or several TSS as for the β1,4-galactosyltransferase 
genes B4GALT4 and B4GALT5 [42,43], the ABO gene [44], the sialyl-
transferase ST6GAL2 [45] and ST6GALNAC1 genes [46] and the β1,6-N- 
acetylglucosaminyltransferase GCNT1 gene ([47]. 
4.2. Delineation of the core promoter and identification of TF implicated 
in B4GALNT2 gene expression 
The 5′-flanking region of the human B4GALNT2 gene was cloned and 
characterized, and a GC-rich promoter region (− 83/+72) lacking the 
canonical TATA and CCAAT boxes was delineated. This genomic region 
contained the positive regulatory elements responsible for constitutive 
activity, regardless of the recipient cell. Furthermore, we defined the 
main promoter orchestrating the expression of the short B4GALNT2 
variant and identified major Cis-acting regulatory elements required for 
accurate and efficient initiation of B4GALNT2 transcription. 
This region was analyzed by MatInspector program (Genomatix) 
revealing three SP1-binding sites (SP1.1 (− 73/− 64); SP1.2 (− 18/− 8); 
SP1.3 (+8/+17)) (Fig. 3A). Site directed mutagenesis of each site un-
covered that SP1.1 could be involved in promoter activation, whereas 
SP1.2 and SP1.3 could be involved in promoter repression. SP1 is a well- 
known zinc finger TF that belongs to the Specificity Protein/Krüppel- 
like Factor (SP/KLF) TF family. It is widely expressed in all mammalian 
cells and is characterized by the highly conserved (sequence identity 
more than 65%) GC-rich DNA binding domain [48]. UALCAN portal 
analysis [24] of Colorectal Adenocarcinoma (COAD) samples from 
TCGA database showed no significant changes in the SP1 expression 
levels (Supplemental Fig. S3). However, using TCGA and Colonomics 
database, we were not able to show a significantly positive correlation 
between B4GALNT2 and SP1 expression (r = 0.29, p = 0.04386) in 
healthy mucosa samples (Fig. 7). Other TF of the SP/KLF family sharing 
the same DNA binding site like SP3 have comparable enhancing and 
inhibitory activity depending on cell context. SP1 gene expression is 
regulated during development, cell differentiation, tumorigenesis and 
plays opposite roles in cancer [49]. The bioinformatic analysis of this 
region also led to the identification of ETS1 putative binding site at 
positions − 33/− 25 (Fig. 3A). ETS family members are evolutionarily 
conserved TF that share a highly conserved purine-rich DNA-binding 
motif (i.e. GGAA/T ETS domain) in the promoter/enhancer regions of 
many genes. ETS genes are multifaceted TFs since they have been 
implicated in both in cell proliferation and differentiation, and in tumor 
formation and metastasis and can be viewed as tumor-suppressor 
[50,51]. Indeed, overexpression of ETS1 in HCT-116 cells that do not 
express this TF (Supplemental Fig. S2) was shown to suppress tumori-
genicity [52] and ETS1 levels of expression decreased slightly, but 
significantly (statistical significance = 8.89E-03) in the COAD primary 
tumor of the TCGA database (Supplemental Figs. S3A and S3B). This was 
Fig. 5. Effect of ETS1, SP1 and DMTF1 overexpression (A) or silencing (B) on 
the relative expression of B4GALNT2 SF transcripts in CCD-841-CoN cells. (A) 
CCD-841-CoN cells were transiently transfected with an empty vector (Mock) or 
pcDNA3-ETS1, pCMV4-SP1, pcDNA3-DMTF1 expression vector. After 48 h, 
total RNA was extracted and the short B4GALNT2 transcript variants were 
quantified by qPCR as described previously [9]. (B) CCD-841-CoN cells were 
transiently transfected with control siRNA or specific siRNA targeting ETS1, 
SP1, or DMTF1. After 48 h, total RNA was extracted and the short B4GALNT2 
transcript variants were quantified by qPCR as described previously [9]. Data 
are means +/- SD of three independent experiments. *: p ≤ 0.05; **: p ≤ 0.01; 
***: p < 0.001; ns: non-significant (vs Mock). 
Fig. 6. Endogenous binding of SP1 and ETS1 on the B4GALNT2 promoter in 
CCD 841 CoN cells. Chromatin immunoprecipitation was performed as 
described in the materials and methods section from CCD 841 CoN cells. 
Quantitative PCR were carried out with a specific pair of primers covering 
either the SP1 or the ETS1 binding sites (Supplemental Table 5). The percentage 
of input was calculated from ChIP samples obtained with irrelevant (Ctrl IgG) or 
specific antibodies (either anti-SP1 or anti-ETS1) normalized to the adjusted 
input values. 
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accompanied with a positive and significant correlation between 
B4GALNT2 and ETS1 gene expression both in the TCGA COADREAD (r 
= 0.24, p < 0.00001) and healthy mucosa from Colonomics (r = 0.40, p 
= 0.00413) datasets (Fig. 7). Of particular interest is the observation 
that in many cases, the affinity of the ETS proteins to their DNA targets is 
increased by association with other transcription factors including, 
among others, AP1, SP1, CBF, C/EBP and SRF [53,54]. In this study, we 
identified a putative DMTF1 (cyclin D binding myb-like protein 1) 
binding site that overlapped the ETS1 binding site in the B4GALNT2 
promoter region (Fig. 3A). DMTF1 also known as DMP1 is a TF that was 
isolated in a yeast two-hybrid screen through its binding property to 
cyclin D2 [55] and its expression is ambiguous because shown as 
decreased in colorectal cancer cells (CRC) cells in [56], but shown as 
slightly increasing in TCGA data (supplemental Fig. S3A), which can be 
due to the fact that a high heterogeneity is observed for DMTF1 
expression in tumorous tissues (Supplemental Fig. S3A and S3B). 
DMTF1 specifically binds to the DNA consensus sequences CCCG(G/T) 
ATGT to activate transcription. As identified in the B4GALNT2 pro-
moter, some DMTF1 binding sites contain a GGA core that could serve as 
a ETS1-responsive element [25,57]. Our mutagenesis analysis on each 
ETS1 and DMTF1 potential binding site showed a significant effect on 
the promoter activity. When DMTF1 binding site was deleted our data 
suggested that ETS1-binding only significantly increased the B4GALNT2 
promoter activity, whereas mutation of the ETS1 site did not change 
significantly its activity (Fig. 4). This observation was supported by our 
ChIP data carried out in CCD 841 CoN showing fixation of ETS1 (Fig. 6) 
but not of DMTF1 (data not shown). In accordance with these results, we 
were not able to identify positive correlations of expression between 
B4GALNT2 and DMTF1 in our analysis (Fig. 7). Finally, mutation of both 
TF binding sites led to a significant silencing of the promoter activity 
(Fig. 4), further suggesting that the combination of both ETS1 and 
DMTF1 is necessary to activate the B4GALNT2 promoter. Further 
silencing and overexpression of these TF in CCD 841 CoN showed that a 
decreased expression of ETS1 and SP1 conducted to a decreased 
expression of the B4GALNT2 SF-type transcript variant, whereas an 
increased expression of ETS1, likely combined to endogenous DMTF1 in 
CCD 841 CoN led to an increased expression of the B4GALNT2 SF-type 
variant (Fig. 5). 
Fig. 7. Gene expression correlation be-
tween B4GALNT2 and ETS1, SP1 and 
DMTF1 transcription factor encoding 
genes in normal and tumor patient 
samples. (A-B) Triangular heat maps 
representing gene correlation analysis 
in normal and cancer colon tissues. (A) 
Correlation Pearson r values were 
calculated for each transcript combina-
tion from the COADREAD cohort (n =
524). (B) Correlation Pearson r values 
were calculated for each transcript 
combination from normal tissues 
(healthy mucosa) of the Colonomics 
cohort (n = 50). Cut off values for pos-
itive or negative correlation were set at 
0.2 and − 0.1, respectively. Correlation 
coefficient are depicted according to the 
color scale: the strongest positive and 
the strongest negative correlations are 
shown in red and blue, respectively. (C) 
Heat map showing the expression of the 
B4GALNT2 gene and ETS1, SP1 and 
DMTF1 transcription factor encoding 
genes in all Colonomics samples 
(GSE44076). Columns of the matrix 
correspond to the expression of each 
gene of interest and rows correspond to 
normal (in green), adjacent (in blue) 
and tumor (in pink) samples. The indi-
vidual tiles in the heat map are scaled 
by rows with a range of colors propor-
tionate to gene expression values in 
each sample (row z-score). The red and 
blue colors in tiles reflect relatively high 
and low expression levels, respectively, 
as indicated by the scale bar.   
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4.3. Glyco-gene network regulated by ETS1/SP1/DMTF1/CREB3L1 
Despite the fact that transcriptional regulation is recognized as a 
major regulator of glycan expression [13,58], very little is known about 
TF-mediated control of glyco-genes. In an attempt to obtain a general 
picture for gene regulatory network centered on B4GALNT2, a list of 45 
genes including the three transcription factors ETS1, SP1 and DMTF1 
identified in our study (Supplemental data) and 42 glyco-genes 
belonging to the same pathways as B4GALNT2 and involved in the ter-
minal biosynthetic steps of the Sda epitope on N-glycans, O-glycans and 
glycolipids [59] was created. Since the major components of the mucus 
layer in the gastrointestinal tract are heavily O-glycosylated mucin 
proteins like MUC2 and MUC5B [60,61] these genes were also included 
in the list. In addition, several glycosyltransferase genes with variable 
expression levels in lower and higher B4GALNT2 expresser CRC patients 
[16] including ST6GAL1, ST6GAL2, B3GNT7, ST6GALNAC1, ST6GAL-
NAC6, B3GNT6 were added to the list. Their master TF regulators were 
then searched with the iRegulon program (see material and method 
section) which is based on the enrichment of binding motifs of regula-
tory factors. We chose the option to search in the 500 bp upstream the 
TSS including the regulatory region we identified in our work. A regu-
latory network considering only the targets of the three TFs and the 
master regulators of B4GALNT2 was visualized with Cytoscape (Fig. 8). 
We also integrated differentially expressed signals between primary 
tumor and normal tissues of the COAD data from UALCAN in the 
network and colored the genes as a gradient from blue to white and red, 
accordingly. Even if not significantly differentially expressed, it mainly 
shows CREB3L1 (cAMP responsive element binding protein 3 like 1), a 
TF that represses expression of genes regulating metastasis, invasion, 
and angiogenesis and regulates the unfolded protein response (UPR) in 
the ER [62] (Fig. 8). DMTF1 was not identified as a regulator likely 
because of a lack of knowledge concerning this TF. However, SP1 shows 
a wide putative regulation in the three biosynthetic pathways, in 
particular in the O-Glycans synthesis pathway. The network also shows 
potential regulation by ETS1, making it a very central TF. ETS1 is 
slightly but significantly lowered in primary tumors and motifs for the 
binding of ETS1 appear in the promoter of several glyco-genes involved 
in N-Glycans and glycolipids synthesis like B4GALT1, which is also 
repressed in primary tumors. Some motifs also appear at various levels 
of O-Glycans synthesis (ST3GAL2 and MUC1). However, they show 
different variations in their signals depicting a more advanced regula-
tion than simple direct TF-target one. The figure shows that the regu-
lations of B4GALNT2 by SP1, ETS1 and potentially DMTF1 may not be 
limited to this gene, but likely affect the expression of other genes of 
these three biosynthetic pathways, like MUC1, eventually regulated by 
ETS1 and which was shown by [16] to exhibit co-expression with 
B4GALNT2, although not differentially expressed in TCGA. Interest-
ingly, this later work highlighted other co-expressed glyco-genes like 
Fig. 8. Regulatory network of glyco-genes involved in the N-Glycans, O-Glycans and glycolipids biosynthesis pathways; the network was built with the iRegulon app 
for Cytoscape, keeping the regulators of B4GALNT2 (grey) and the targets of ETS1, SP1 and DMTF1 (green); the regulations identified experimentally in our work are 
colored black; thickness of the edges corresponds to the number of times a motif of the transcription factor was found by iRegulon in the 500 bp upstream the 
transcription start site; glyco-genes are colored in function of their membership to one or several biosynthetic pathways: O-Glycans (red), N-Glycans (blue) or 
glycolipids (yellow), the ones that belong to several pathways are colored with a mixture of these primary colors; genes found as co-differentially expressed with 
B4GALNT2 in the work of Pucci et al. [4] are shown as elliptic nodes; log2 fold change between primary tumor (COAD) and normal tissue from the UALCAN Portal 
were integrated in the network. Genes are colored as a gradient from blue (log2FC ≤ − 3) to white (log2FC = 0) and red (log2FC ≥ 3), only signals with statistical 
significance ≤0.05 were colored, others are white. 
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MUC4, B3GNT7, MUC5B, B3GNT6, ST6GALNAC6, ST6GAL1, ST6GAL2 
and MUC2 also identified here as regulated by SP1 and/or CREB3L1 TFs 
(see ellipses in Fig. 8) and repressed for a majority of them, making in 
particular the N-glycans biosynthesis pathway globally repressed in the 
network (see also supplemental Fig. S3B). SP1 and/or ETS1 regulation 
was already described for B4GALT5 in cancer cells [42,63] and for 
B4GALT4 [43], two β1,4-galactosyltransferases involved in the N- and 
O-glycan elongation. Previous studies also demonstrated implication of 
SP1 in the transcriptional regulation of the α2,3-sialyltransferase 
ST3GAL1 [64] involved in O-glycans sialylation and ST3GAL3 [65] 
involved in the sialylation of O- and N-glycans and of glycolipids. 
Altogether, these observations further nurture the idea of a complex 
regulation of the glyco-genes involved in the Sda biosynthetic pathways 
by mechanisms that involve the three TFs. 
4.4. Other transcriptional regulation, surrounding genomic region 
However, our data do not fully explain the molecular mechanisms 
underpinning Sda/Cad expression in the healthy colon and its disap-
pearance in the cancerous colon and beyond TFs, other regulatory 
mechanisms are likely involved in B4GALNT2 transcriptional 
regulation. 
Epigenetic modifications like DNA methylation in the promoter re-
gion of the B4GALNT2 gene were reported to downregulate expression 
of this gene in cancer cell lines like HCT-116 and gastric Kato III cells 
[14,15]. In this regard, we obtained evidences that overexpression of 
ETS1 in HCT-116 did not induced expression of the B4GALNT2 SF-type 
transcript (data not shown). This observation could be explained by CpG 
island methylation of the B4GALNT2 promoter in these cells that would 
impair ETS1 binding. Of particular interest is the recent study of Pucci 
et al. reporting the existence of DNA methylation of an intronic site 
located between exon 6 and exon 7 [16] that drives increased expression 
of the B4GALNT2 gene. Other epigenetic modifications include histone 
modifications (i.e. acetylation and methylation). In the past, Kawamura 
and collaborators obtained evidences using the histone deacetylase in-
hibitor butyrate that these histone modifications would not be primarily 
involved in B4GALNT2 gene regulation [14]. 
Additional long-range regulatory elements with enhancer motifs 
could be located far upstream the B4GALNT2 gene and could account for 
the tissue specificity expression of the B4GALNT2 gene. Indeed, in the 
RIIIS/J mouse strain, a conserved region located 30 kb upstream of the 
gene was described for the b4galnt2 locus in mice, where a mutation is 
responsible for low plasma levels of the von Willebrand factor (VWF). 
This mutation causes a regulatory switch in the b4galnt2 expression 
leading to its expression in the vascular endothelium and its concomi-
tant disappearance in colon [66]. We conducted BLAST analysis in 
various mammalian genomes and our preliminary data led to the iden-
tification of a ~ 400 bp highly conserved genomic region located 9623, 
19,046, 22,671, 27,654, 47,610, 50,276 and 30,571 bp upstream the 
b4galnt2 gene in Otolemur garnettii, Bos taurus, Loxodonta Africana, Ovis 
aries, Macaca mulatta, Homo sapiens and Mus musculus (data not shown). 
Further experimental data are needed to support this finding. 
Downstream genomic region could be also implicated in the 
B4GALNT2 transcriptional regulation. Beside the well-established role 
of TF, noncoding RNAs (ncRNAs) are new regulators of great interest 
and among these, microRNAs (miRNAs) are the most studied. Long 
noncoding RNAs (lncRNAs) are non-translated RNA transcripts of more 
than 200 nucleotides [67,68]. Their expression is tissue-specific and 
changes observed in a tissue have been correlated with various human 
pathologies like cancer [68]. Of particular interest is the lncRNA RP11- 
708H21.4, a locus found at 17q21. It corresponds to a 1352 nt sequence 
in the 3′-untranslated region of the B4GALNT2 gene. It was found to be 
downregulated in colorectal cancer and could inhibit tumorigenesis 
through CyclinD1 and p27 expression regulation [68]. Furthermore, the 
upregulation of lncRNA RP11-708H21.4 inhibits migration and inva-
sion, induces apoptosis, and enhances 5-FU sensitivity in CRC cells by 
inactivating mTOR signaling. 
In summary, this study shed light on the molecular basis of Sda 
expression in the human gastrointestinal tract. We identified TSS and 
delineate the − 72/+12 nt core promoter region of the B4GALNT2 gene 
relative to the short-type transcript variant. We identified ETS1 as a 
major regulator of its expression in colon although further studies are 
required to elucidate precisely how B4GALNT2 expression is controlled 
in healthy colon and deregulated in colon cancer. 
Supplementary data to this article can be found online at https://doi. 
org/10.1016/j.bbagrm.2021.194747. 
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[3] L. Stenfelt, Å. Hellberg, M. Möller, N. Thornton, G. Larson, M.L. Olsson, Missense 
mutations in the C-terminal portion of the B4GALNT2-encoded glycosyltransferase 
underlying the Sd(a− ) phenotype, Biochem. Biophys. Rep. 19 (2019), 100659. 
C. Wavelet-Vermuse et al.                                                                                                                                                                                                                     
BBA - Gene Regulatory Mechanisms 1864 (2021) 194747
12
[4] F. Dall’Olio, N. Malagolini, M. Chiricolo, M. Trinchera, A. Harduin-Lepers, The 
expanding roles of the Sd(a)/Cad carbohydrate antigen and its cognate 
glycosyltransferase B4GALNT2, Biochim. Biophys. Acta 1840 (2014) 443–453. 
[5] C. Capon, E. Maes, J.C. Michalski, H. Leffler, Y.S. Kim, Sd(a)-antigen-like structures 
carried on core 3 are prominent features of glycans from the mucin of normal 
human descending colon, Biochem. J. 358 (2001) 657–664. 
[6] K. Madunic, T. Zhang, O.A. Mayboroda, S. Holst, K. Stavenhagen, C. Jin, N. 
G. Karlsson, G.S.M. Lageveen-Kammeijer, M. Wuhrer, Colorectal cancer cell lines 
show striking diversity of their O-glycome reflecting the cellular differentiation 
phenotype, Cell. Mol. Life Sci. 78 (2021) 337–350, https://doi.org/10.1007/ 
s00018-020-03504-z. 
[7] L. Lo Presti, E. Cabuy, M. Chiricolo, F. Dall’Olio, Molecular cloning of the human 
beta1,4 N-acetylgalactosaminyltransferase responsible for the biosynthesis of the 
Sd(a) histo-blood group antigen: the sequence predicts a very long cytoplasmic 
domain, J. Biochem. 134 (2003) 675–682. 
[8] M.D. Montiel, M.A. Krzewinski-Recchi, P. Delannoy, A. Harduin-Lepers, Molecular 
cloning, gene organization and expression of the human UDP-GalNAc: 
Neu5Acalpha2-3Galbeta-R beta1,4-N-acetylgalactosaminyltransferase responsible 
for the biosynthesis of the blood group Sda/Cad antigen: evidence for an unusual 
extended cytoplasmic domain, Biochem. J. 373 (2003) 369–379. 
[9] S. Groux-Degroote, C. Wavelet, M.A. Krzewinski-Recchi, L. Portier, M. Mortuaire, 
A. Mihalache, M. Trinchera, P. Delannoy, N. Malagolini, M. Chiricolo, F. Dall’Olio, 
A. Harduin-Lepers, B4GALNT2 gene expression controls the biosynthesis of Sda 
and sialyl Lewis X antigens in healthy and cancer human gastrointestinal tract, Int. 
J. Biochem. Cell Biol. 53 (2014) 442–449. 
[10] T. Dohi, A. Nishikawa, I. Ishizuka, M. Totani, K. Yamaguchi, K. Nakagawa, 
O. Saitoh, S. Ohshiba, M. Oshima, Substrate specificity and distribution of UDP- 
GalNAc:sialylparagloboside N-acetylgalactosaminyltransferase in the human 
stomach, Biochem. J. 288 (Pt 1) (1992) 161–165. 
[11] N. Malagolini, D. Santini, M. Chiricolo, F. Dall’Olio, Biosynthesis and expression of 
the Sda and sialyl Lewis x antigens in normal and cancer colon, Glycobiology 17 
(2007) 688–697. 
[12] S. Groux-Degroote, C. Schulz, V. Cogez, M. Noel, L. Portier, D. Vicogne, 
C. Solorzano, F. Dall’Olio, A. Steenackers, M. Mortuaire, M. Gonzalez-Pisfil, 
M. Henry, F. Foulquier, L. Heliot, A. Harduin-Lepers, The extended cytoplasmic tail 
of the human B4GALNT2 is critical for its Golgi targeting and post-Golgi sorting, 
FEBS J. 285 (2018) 3442–3463. 
[13] S. Neelamegham, L.K. Mahal, Multi-level regulation of cellular glycosylation: from 
genes to transcript to enzyme to structure, Curr. Opin. Struct. Biol. 40 (2016) 
145–152. 
[14] Y.I. Kawamura, M. Toyota, R. Kawashima, T. Hagiwara, H. Suzuki, K. Imai, 
Y. Shinomura, T. Tokino, R. Kannagi, T. Dohi, DNA hypermethylation contributes 
to incomplete synthesis of carbohydrate determinants in gastrointestinal cancer, 
Gastroenterology 135 (2008) (142-151 e143). 
[15] H.R. Wang, C.Y. Hsieh, Y.C. Twu, L.C. Yu, Expression of the human Sd(a) beta-1,4- 
N-acetylgalactosaminyltransferase II gene is dependent on the promoter 
methylation status, Glycobiology 18 (2008) 104–113. 
[16] M. Pucci, N. Malagolini, F. Dall’Olio, Glycosyltransferase B4GALNT2 as a predictor 
of good prognosis in colon cancer: lessons from databases, Int. J. Mol. Sci. 22 
(2021) 4331. 
[17] I. Van Seuningen, M. Perrais, P. Pigny, N. Porchet, J.P. Aubert, Sequence of the 5′- 
flanking region and promoter activity of the human mucin gene MUC5B in 
different phenotypes of colon cancer cells, Biochem. J., 348 Pt 3 (2000) 675–686. 
[18] F. Colomb, M.A. Krzewinski-Recchi, A. Steenackers, A. Vincent, A. Harduin-Lepers, 
P. Delannoy, S. Groux-Degroote, TNF up-regulates ST3GAL4 and sialyl-Lewisx 
expression in lung epithelial cells through an intronic ATF2-responsive element, 
Biochem. J. 474 (2017) 65–78. 
[19] N. Jonckheere, A. Velghe, M.P. Ducourouble, M.C. Copin, I.B. Renes, I. 
Van Seuningen, The mouse Muc5b mucin gene is transcriptionally regulated by 
thyroid transcription factor-1 (TTF-1) and GATA-6 transcription factors, FEBS J. 
278 (2011) 282–294. 
[20] M.W. Pfaffl, A new mathematical model for relative quantification in real-time RT- 
PCR, Nucleic Acids Res. 29 (2001), e45. 
[21] R. Janky, A. Verfaillie, H. Imrichova, B. Van de Sande, L. Standaert, V. Christiaens, 
G. Hulselmans, K. Herten, M. Naval Sanchez, D. Potier, D. Svetlichnyy, Z. 
Kalender Atak, M. Fiers, J.C. Marine, S. Aerts, iRegulon: from a gene list to a gene 
regulatory network using large motif and track collections, PLoS Comput. Biol. 10 
(2014), e1003731. 
[22] P. Shannon, A. Markiel, O. Ozier, N.S. Baliga, J.T. Wang, D. Ramage, N. Amin, 
B. Schwikowski, T. Ideker, Cytoscape: a software environment for integrated 
models of biomolecular interaction networks, Genome Res. 13 (2003) 2498–2504. 
[23] G. Su, J.H. Morris, B. Demchak, G.D. Bader, Biological network exploration with 
Cytoscape 3, Curr. Protoc. Bioinformatics 47 (2014) (8 13 11-24). 
[24] D.S. Chandrashekar, B. Bashel, S.A.H. Balasubramanya, C.J. Creighton, I. Ponce- 
Rodriguez, B. Chakravarthi, S. Varambally, UALCAN: a portal for facilitating tumor 
subgroup gene expression and survival analyses, Neoplasia 19 (2017) 649–658. 
[25] H. Hirai, C.J. Sherr, Interaction of D-type cyclins with a novel myb-like 
transcription factor, DMP1, Mol. Cell. Biol. 16 (1996) 6457–6467. 
[26] T. Dohi, Y. Yuyama, Y. Natori, P.L. Smith, J.B. Lowe, M. Oshima, Detection of N- 
acetylgalactosaminyltransferase mRNA which determines expression of Sda blood 
group carbohydrate structure in human gastrointestinal mucosa and cancer, Int. J. 
Cancer 67 (1996) 626–631. 
[27] N. Malagolini, F. Dall’Olio, G. Di Stefano, F. Minni, D. Marrano, F. Serafini-Cessi, 
Expression of UDP-GalNAc:NeuAc alpha 2,3Gal beta-R beta 1,4(GalNAc to Gal) N- 
acetylgalactosaminyltransferase involved in the synthesis of Sda antigen in human 
large intestine and colorectal carcinomas, Cancer Res. 49 (1989) 6466–6470. 
[28] M. Pucci, I. Gomes Ferreira, N. Malagolini, M. Ferracin, F. Dall’Olio, The Sda 
synthase B4GALNT2 reduces malignancy and stemness in colon cancer cell lines 
independently of Sialyl Lewis X inhibition, Int. J. Mol. Sci. 21 (2020) 6558. 
[29] M. Pucci, I. Gomes Ferreira, M. Orlandani, N. Malagolini, M. Ferracin, F. Dall’Olio, 
High expression of the Sda synthase B4GALNT2 associates with good prognosis and 
attenuates stemness in colon cancer, Cells 9 (2020) 948. 
[30] A. Galeev, A. Suwandi, A. Cepic, M. Basu, J.F. Baines, G.A. Grassl, The role of the 
blood group-related glycosyltransferases FUT2 and B4GALNT2 in susceptibility to 
infectious disease, Int. J. Med. Microbiol. 311 (2021), 151487. 
[31] P.L. Smith, J.B. Lowe, Molecular cloning of a murine N-acetylgalactosamine 
transferase cDNA that determines expression of the T lymphocyte-specific CT 
oligosaccharide differentiation antigen, J. Biol. Chem. 269 (1994) 15162–15171. 
[32] K. Furukawa, H. Soejima, N. Niikawa, H. Shiku, Genomic organization and 
chromosomal assignment of the human beta1, 4-N-acetylgalactosaminyltransferase 
gene. Identification of multiple transcription units, J. Biol. Chem. 271 (1996) 
20836–20844. 
[33] A. Harduin-Lepers, J.H. Shaper, N.L. Shaper, Characterization of two cis-regulatory 
regions in the murine beta 1,4-galactosyltransferase gene. Evidence for a negative 
regulatory element that controls initiation at the proximal site, J. Biol. Chem. 268 
(1993) 14348–14359. 
[34] A. Harduin-Lepers, N.L. Shaper, J.A. Mahoney, J.H. Shaper, Murine beta 1,4-gal-
actosyltransferase: round spermatid transcripts are characterized by an extended 
5′-untranslated region, Glycobiology 2 (1992) 361–368. 
[35] S.W. Kim, S.H. Lee, K.S. Kim, C.H. Kim, Y.K. Choo, Y.C. Lee, Isolation and 
characterization of the promoter region of the human GM3 synthase gene, 
Biochim. Biophys. Acta 1578 (2002) 84–89. 
[36] E.C. Svensson, P.B. Conley, J.C. Paulson, Regulated expression of alpha 2,6-sia-
lyltransferase by the liver-enriched transcription factors HNF-1, DBP, and LAP, 
J. Biol. Chem. 267 (1992) 3466–3472. 
[37] E.C. Svensson, B. Soreghan, J.C. Paulson, Organization of the beta-galactoside 
alpha 2,6-sialyltransferase gene. Evidence for the transcriptional regulation of 
terminal glycosylation, J. Biol. Chem. 265 (1990) 20863–20868. 
[38] D. Petit, A.M. Mir, J.M. Petit, C. Thisse, P. Delannoy, R. Oriol, B. Thisse, 
A. Harduin-Lepers, Molecular phylogeny and functional genomics of beta- 
galactoside alpha2,6-sialyltransferases that explain ubiquitous expression of 
st6gal1 gene in amniotes, J. Biol. Chem. 285 (2010) 38399–38414. 
[39] M. Bobovski, A. Harduin-Lepers, P. Delannoy, ST8alpha-N-acetyl-neuraminide 
alpha-2,8-sialyltransferase 1 (ST8SIA1), in: N. Taniguchi, K. Honke, M. Fukuda, 
H. Narimatsu, Y. Yamaguchi, T. Angata (Eds.), Handbook of Glycosyltransferases 
and Related Genes, Springer-Verlag GmbH, 2013. 
[40] K. Furukawa, M. Horie, K. Okutomi, S. Sugano, K. Furukawa, Isolation and 
functional analysis of the melanoma specific promoter region of human GD3 
synthase gene, Biochim. Biophys. Acta 1627 (2003) 71–78. 
[41] R. Tange, T. Tomatsu, T. Sato, Transcription of human beta4-galactosyltransferase 
3 is regulated by differential DNA binding of Sp1/Sp3 in SH-SY5Y human 
neuroblastoma and A549 human lung cancer cell lines, Glycobiology 29 (2019) 
211–221. 
[42] T. Sato, K. Furukawa, Transcriptional regulation of the human beta-1,4- 
galactosyltransferase V gene in cancer cells: essential role of transcription factor 
Sp1, J. Biol. Chem. 279 (2004) 39574–39583. 
[43] A. Sugiyama, N. Fukushima, T. Sato, Transcriptional mechanism of the beta4- 
galactosyltransferase 4 gene in SW480 human colon cancer cell line, Biol. Pharm. 
Bull. 40 (2017) 733–737. 
[44] F. Yamamoto, P.D. McNeill, S. Hakomori, Genomic organization of human histo- 
blood group ABO genes, Glycobiology 5 (1995) 51–58. 
[45] S. Lehoux, S. Groux-Degroote, A. Cazet, C.M. Dhaenens, C.A. Maurage, M.L. Caillet- 
Boudin, P. Delannoy, M.A. Krzewinski-Recchi, Transcriptional regulation of the 
human ST6GAL2 gene in cerebral cortex and neuronal cells, Glycoconj. J. 27 
(2010) 99–114, https://doi.org/10.1007/s10719-009-9260-y. 
[46] N. Kurosawa, S. Takashima, M. Kono, Y. Ikehara, M. Inoue, Y. Tachida, 
H. Narimatsu, S. Tsuji, Molecular cloning and genomic analysis of mouse GalNAc 
alpha2, 6-sialyltransferase (ST6GalNAc I), J. Biochem. 127 (2000) 845–854. 
[47] V.R. Falkenberg, K. Alvarez, C. Roman, N. Fregien, Multiple transcription initiation 
and alternative splicing in the 5′ untranslated region of the core 2 beta1-6 N- 
acetylglucosaminyltransferase I gene, Glycobiology 13 (2003) 411–418. 
[48] L. Li, J.R. Davie, The role of Sp1 and Sp3 in normal and cancer cell biology, Ann. 
Anat. 192 (2010) 275–283. 
[49] K. Beishline, J. Azizkhan-Clifford, Sp1 and the ‘hallmarks of cancer’, FEBS J. 282 
(2015) 224–258. 
[50] T. Hsu, M. Trojanowska, D.K. Watson, Ets proteins in biological control and cancer, 
J. Cell. Biochem. 91 (2004) 896–903. 
[51] D.P. Turner, D.K. Watson, ETS transcription factors: oncogenes and tumor 
suppressor genes as therapeutic targets for prostate cancer, Expert. Rev. 
Anticancer. Ther. 8 (2008) 33–42. 
[52] H. Suzuki, V. Romano-Spica, T.S. Papas, N.K. Bhat, ETS1 suppresses tumorigenicity 
of human colon cancer cells, Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 4442–4446. 
[53] B.J. Graves, J.M. Petersen, Specificity within the ets family of transcription factors, 
Adv. Cancer Res. 75 (1998) 1–55. 
[54] F. Shirasaki, H.A. Makhluf, C. LeRoy, D.K. Watson, M. Trojanowska, Ets 
transcription factors cooperate with Sp1 to activate the human tenascin-C 
promoter, Oncogene 18 (1999) 7755–7764. 
[55] M.P. Tschan, K.M. Fischer, V.S. Fung, F. Pirnia, M.M. Borner, M.F. Fey, A. Tobler, 
B.E. Torbett, Alternative splicing of the human cyclin D-binding Myb-like protein 
(hDMP1) yields a truncated protein isoform that alters macrophage differentiation 
patterns, J. Biol. Chem. 278 (2003) 42750–42760. 
C. Wavelet-Vermuse et al.                                                                                                                                                                                                                     
BBA - Gene Regulatory Mechanisms 1864 (2021) 194747
13
[56] X. Yang, Y. Lou, M. Wang, C. Liu, Y. Liu, W. Huang, miR675 promotes colorectal 
cancer cell growth dependent on tumor suppressor DMTF1, Mol. Med. Rep. 19 
(2019) 1481–1490. 
[57] K. Inoue, A. Mallakin, D.P. Frazier, Dmp1 and tumor suppression, Oncogene 26 
(2007) 4329–4335. 
[58] H. Guo, M.J. Pierce, Transcriptional regulation of glycan expression, in: 
N. Taniguchi, T. Endo, G.W. Hart, P.H. Seeberger, C.-H. Wong (Eds.), Glycoscience: 
Biology and Medicine vol. 2, Springer Japan, Japan, 2015, pp. 1173–1180. 
[59] Y. Narimatsu, H.J. Joshi, R. Nason, J. Van Coillie, R. Karlsson, L. Sun, Z. Ye, Y.- 
H. Chen, K.T. Schjoldager, C. Steentoft, S. Furukawa, B.A. Bensing, P.M. Sullam, A. 
J. Thompson, J.C. Paulson, C. Büll, G.J. Adema, U. Mandel, L. Hansen, E. 
P. Bennett, A. Varki, S.Y. Vakhrushev, Z. Yang, H. Clausen, An atlas of human 
glycosylation pathways enables display of the human glycome by gene engineered 
cells, Mol. Cell 75 (2019) (394-407.e395). 
[60] M. Andrianifahanana, N. Moniaux, S.K. Batra, Regulation of mucin expression: 
mechanistic aspects and implications for cancer and inflammatory diseases, 
Biochim. Biophys. Acta 1765 (2006) 189–222. 
[61] N. Jonckheere, A. Vincent, B. Neve, I. Van Seuningen, Mucin expression, epigenetic 
regulation and patient survival: a toolkit of prognostic biomarkers in epithelial 
cancers, Biochim. Biophys. Acta Rev. Cancer 1876 (2021), 188538. 
[62] P. Mellor, L. Deibert, B. Calvert, K. Bonham, S.A. Carlsen, D.H. Anderson, CREB3L1 
is a metastasis suppressor that represses expression of genes regulating metastasis, 
invasion, and angiogenesis, Mol. Cell. Biol. 33 (2013) 4985–4995. 
[63] T. Sato, K. Furukawa, Sequential action of Ets-1 and Sp1 in the activation of the 
human beta-1,4-galactosyltransferase V gene involved in abnormal glycosylation 
characteristic of cancer cells, J. Biol. Chem. 282 (2007) 27702–27712. 
[64] A. Taniguchi, I. Yoshikawa, K. Matsumoto, Genomic structure and transcriptional 
regulation of human Galbeta1,3GalNAc alpha2,3-sialyltransferase (hST3Gal I) 
gene, Glycobiology 11 (2001) 241–247. 
[65] A. Taniguchi, K. Saito, T. Kubota, K. Matsumoto, Characterization of the promoter 
region of the human Galbeta1,3(4)GlcNAc alpha2,3-sialyltransferase III (hST3Gal 
III) gene, Biochim. Biophys. Acta 1626 (2003) 92–96. 
[66] K.L. Mohlke, A.A. Purkayastha, R.J. Westrick, P.L. Smith, B. Petryniak, J.B. Lowe, 
D. Ginsburg, Mvwf, a dominant modifier of murine von Willebrand factor, results 
from altered lineage-specific expression of a glycosyltransferase, Cell 96 (1999) 
111–120. 
[67] T. Derrien, R. Guigo, R. Johnson, The long non-coding RNAs: a new (P)layer in the 
“dark matter”, Front. Genet. 2 (2011) 107. 
[68] R. Zhang, F. Ni, B. Fu, Y. Wu, R. Sun, Z. Tian, H. Wei, A long noncoding RNA 
positively regulates CD56 in human natural killer cells, Oncotarget 7 (2016) 
72546–72558. 
C. Wavelet-Vermuse et al.                                                                                                                                                                                                                     
